The U.S. Court of Appeals for the Federal Circuit will not revive a $2.5 billion jury award that Merck & Co. and subsidiary Idenix Pharmaceuticals won against Gilead Sciences in 2016.
The Federal Circuit agreed with U.S. District Judge Leonard Stark of the District of Delaware that Idenix’s 7,608,597 patent claimed far too many potential compounds to identify the specific 2′-methyl-up modified nucleoside that Gilead uses to treat hepatitis C.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Not a Bloomberg Law Subscriber?
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]